| Home | E-Submission | Sitemap | Contact us |  
top_img
Korean J Pancreas Biliary Tract > Volume 1(2):1996 > Article
The Korean Journal of Pancreas and Biliary Tract 1996;1(2):243-250.
췌장암에서 혈청 CA 19-9와 CA 125의 유용성
이천균, 정재복, 송시영, 강진경, 박인서
연세대학교 의과대학 내과학교실 및 소화기병연구소
Serun CA 19-9 and CA 125 in Pancreatic Cancer
Chun Kyon Lee, Jae Bock Chung, Si Young Song, Jin Kyung Kang, In Suh Park
Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
Corresponding author:  Jae Bock Chung,
ABSTRACT
Background/Aims:
Trial to diagnose pancreatic cancer with CA 19-9 and CA125 has been continued, but study is rare to predict extensiveness of pancreatic cancer with CA 19-9 and CA 125. This study is conducted to evaluate the diagnostic accuracy of CA 19-9 and CA 125 for diagnosing pancreatic cancer and verify the usefulness of CA 19-9 and CA 125 to predict extensiveness of pancreatic cancer. Method: The serum level of CA 19-9 or CA 125 were determined by radioimmunometric assay in 218 patients. We analysed 67 cases of pancreatic cancer according to T, N, M stage, size, resectibility to verify the usefulness of CA 19-9 and CA 125 to predict extensiveness of pancreatic cancer. Result: The upper cutoff point of normal range was determined as 37 U/ml for CA 19-9 and 35 U/ml for CA 125 respectively. The sensitivity of CA 19-9 and CA 125 was 67.2% and 44.4% and specificity was 71.4% and 66.7% The sensitivity and specificity of combined analysis was 76.8% and 57.1% respectively. Positive rate of CA 19-9 in patient with pancreatic cancer, benign pancreatic disease, gastrointestinal cancer other than pancreatic cancer was 67.2%, 28.6%, 31.5% respectively and positive rate of CA 125 was 44.4%, 33.3%, 32.4%. The positive rate of CA 19-9 in patient with biliary cancer and stomach cancer was 52.4% and 25.0% and positive rate of CA 125 was 26.3% and 50.5% respectively. So positive rate of CA 19-9 in patient with pancreatic cancer only was higher than other gastrointestinal cancer statistically. The positive rate of CA 19-9 in T3 stage was higher than T1 and T2 stage and the positive rate of CA 125 was higher in unresectable pancreatic cancer statistically. But the positive rate of CA 19-9 and CA 125 was not related with size, lymph node involvement and distant metastasis.
Conclusions:
Combined analysis of CA 19-9 and CA 125 was more sensitive than single analysis. Serum CA 19-9 and CA 125 may be useful to predict resectibility of pancreatic cancer.
Keywords: Pancreatic cancer, CA 19-9, CA 125, Stage, Resectibility
Editorial Office
Korean Pancreatobiliary Association #723 Le Meilleur Jongro Town, Jongro19, Jongro-gu, Seoul 03157, Korea
Tel: +82-2-2285-5145 Fax: +82-2-2285-5146   E-mail: kpba@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © 2023 by Korean Pancreatobiliary Association.     Developed in M2PI